Improving treatments for Mantle Cell Lymphoma
Developing novel therapy to improve outcomes in MCL
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11114064
This research explores a new way to treat Mantle Cell Lymphoma, a type of cancer, by targeting a specific protein that helps cancer cells grow.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11114064 on ClinicalTrials.gov |
What this research studies
Mantle Cell Lymphoma (MCL) is a challenging cancer where current treatments often lead to relapse, and durable responses are rare. This project focuses on a protein called FGFR1, which appears to be overexpressed in MCL patients and linked to poor outcomes. Researchers have found that blocking FGFR1 in lab and animal models can stop cancer cell growth and improve survival. The goal is to understand exactly how FGFR1 helps MCL cells survive and to conduct further preclinical studies to develop a new targeted therapy.
Who could benefit from this research
Good fit: This research is focused on understanding and developing treatments for patients with Mantle Cell Lymphoma, particularly those who have experienced relapse or whose current therapies are no longer effective.
Not a fit: Patients with other types of lymphoma or those whose Mantle Cell Lymphoma is well-controlled by existing therapies may not directly benefit from this specific new approach.
Why it matters
Potential benefit: If successful, this work could lead to a new targeted medication for patients with Mantle Cell Lymphoma, especially those whose cancer has returned or become resistant to current treatments.
How similar studies have performed: Early laboratory and animal studies have shown promising results when targeting the FGFR1 protein in Mantle Cell Lymphoma cells, leading to reduced tumor growth and improved survival.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SEHGAL, LALIT — OHIO STATE UNIVERSITY
- Study coordinator: SEHGAL, LALIT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Induction